Dose modification in enzalutamide and abiraterone plus prednisolone for castration-resistant prostate cancer: A subanalysis from the ENABLE study for PCa.
Nobumichi TanakaKouji IzumiYasushi NakaiTakashi ShimaYuki KatoKoji MitaManabu KamiyamaShogo InoueSeiji HoshiTakehiko OkamuraYuko YoshioHideki EnokidaIppei ChikazawaNoriyasu KawaiKohei HashimotoTakashi FukagaiKazuyoshi ShigeharaShizuko TakaharaAtsushi MizokamiPublished in: The Prostate (2024)
The modified doses of ABI showed better TTPP than the standard dose of ABI and may be a potential treatment option for CRPC patients; however, its mechanism is still unclear, although its ability to suppress AR signaling is equivalent to that of a standard dose.